title: Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium.
abstract: BACKGROUND
  We evaluated the prognostic importance of DNA ploidy in stage I and II endometrioid adenocarcinoma (EAC) of the endometrium with a focus on DNA index.
  
  
  METHODS
  High-resolution DNA ploidy analysis was carried out in tumor material from 937 consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage I and II EAC of the endometrium.
  
  
  RESULTS
  Patients with diploid (N = 728), aneuploid tumor with DNA index ≤ 1.20 (N = 118), aneuploid tumors with DNA index >1.20 (N = 39) and tetraploid tumor (N = 52) had 5-year recurrence rates 8%, 14%, 20% and 12%, respectively. Patients with aneuploid tumor with DNA index >1.20 had a poorer 5-year progression-free survival (67%) and overall survival (72%) compared with the patients with aneuploid tumor with DNA index ≤ 1.20 (81% and 89%, respectively). Aneuploid tumors with DNA index ≤ 1.20 relapsed mainly in the vagina and pelvis, whereas aneuploid tumors with DNA index >1.20 relapsed predominantly outside pelvis.
  
  
  CONCLUSIONS
  The recurrence risk for the patients with aneuploid tumor is higher than the patients with diploid tumor in EAC of the endometrium. Based on DNA index with cut-off 1.20, aneuploid tumors can be separated into two subgroups with different recurrence pattern and survival.
authors.affiliation: Institute for Medical Informatics; Department of Pathology, Oslo University Hospital, Oslo; Center for Cancer Biomedicine.
authors.forename: M
authors.initials: M
authors.lastname: Pradhan
authors.affiliation: Department of Pathology, Oslo University Hospital, Oslo.
authors.forename: V M
authors.initials: VM
authors.lastname: Abeler
authors.affiliation: Institute for Medical Informatics; Center for Cancer Biomedicine; Department of Informatics, University of Oslo, Oslo.
authors.forename: H E
authors.initials: HE
authors.lastname: Danielsen
authors.affiliation: The Norwegian Radium Hospital.
authors.forename: B
authors.initials: B
authors.lastname: Sandstad
authors.affiliation: Department of Gynecological Oncology, Oslo University Hospital, Oslo; Faculty Division, the Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
authors.forename: C G
authors.initials: CG
authors.lastname: Tropé
authors.affiliation: Institute for Medical Informatics; Department of Gynecological Oncology, Oslo University Hospital, Oslo.
authors.forename: G B
authors.initials: GB
authors.lastname: Kristensen
authors.affiliation: Institute for Medical Informatics; Department of Pathology, Oslo University Hospital, Oslo. Electronic address: bjorn.risberg@oslo-universitetssykehus.no.
authors.forename: B Å
authors.initials: BÅ
authors.lastname: Risberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D018269:Carcinoma, Endometrioid / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics*; D016889:Endometrial Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D004717:Endometrium / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D008940:Mitotic Index; D009367:Neoplasm Staging; D011003:Ploidies; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm